AI주식인사이트AI Stock Insight
C

동아에스티

170900KOSPI의약품 제조업

47.1 / 100

Reference Date: 2026-07-24

Financial Score12.0 / 40
News Sentiment18.1 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Rose 6.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dong-A ST, established in 2013 through a spin-off from Dong-A Pharmaceutical, focuses on manufacturing and selling specialty pharmaceuticals, medical devices, and pharmaceutical cosmetics. Key products include Grotrixin, Motiriton, and Suganon, with 2024 sales reaching 697.9 billion won, a 5.1% increase from the previous year. Growth was driven by the biopharmaceutical product Grotrixin and increased overseas exports.

Number of Employees

1,685people

Average Salary

78.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.234.0Point
PBR
0.52Industry Average 0.815.5Point

Lower than industry avg (good)

ROE
-5.45Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
49.87Industry Average 12.430.0Point

4.0x industry avg (risky)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲10.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼110.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -2.8% (declining, 3yr)

Detailed News Sentiment

27 totalPositive 17Neutral 9Negative 1Average Sentiment Score 72.2

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 36,200Won52-week high 55,12552-week low 32,000
1-month return4.0Point

1m +6.78% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral기업설명회(IR)개최(안내공시)2026-07-23
  • Neutral결산실적공시예고(안내공시)2026-07-23
  • Neutral주식등의대량보유상황보고서(약식)2026-07-01